Breaking News, Collaborations & Alliances

Abbott, Galapagos In Autoimmune Pact

Galapagos is eligible to receive milestone payments totaling $1.0 billion

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott and Galapagos have entered into a global collaboration to develop and commercialize an oral, next-generation JAK1 inhibitor for the potential treatment of multiple autoimmune diseases. GLPG0634 is a highly selective JAK1 inhibitor in Phase II development for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases. Results from a recent Phase IIa study of GLPG0634 demonstrated positive efficacy measures in RA. An additional Phase IIa dose-range finding study is expected to...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters